Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15770168 | 0.86 | PKM (0.39) | PKMHTTALDH1A1LMNAKMT2A | |
| SCHEMBL15769872 | 0.75 | PKM (0.40) | PKMHTTALDH1A1LMNAKMT2A | |
| SCHEMBL30721396 | 0.70 | ALDH1A1 (0.47) | PKMHTTALDH1A1LMNAKMT2A | |
| SCHEMBL29655263 | 0.70 | CYP1A2 (0.44) | AAK1HTTALDH1A1LMNAKMT2A | |
| SCHEMBL951700 | 0.70 | CYP1A2 (0.44) | AAK1HTTALDH1A1LMNAKMT2A | |
| SCHEMBL15769992 | 0.69 | MAPT (0.51) | HTTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL20683228 | 0.68 | MAPK1 (0.48) | PKMHTTALDH1A1LMNAKMT2A | |
| SCHEMBL15710244 | 0.67 | PKM (0.54) | PKMALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL20517236 | 0.67 | MEN1 (0.38) | AAK1HTTALDH1A1LMNAKMT2A | |
| SCHEMBL30997911 | 0.66 | MEN1 (0.40) | AAK1HTTALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| EP-4534538-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3808749-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES | VERTEX PHARMA (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-28 | — | — | US | disclosed |
| US-11117900-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3486245-B1 | 2-AMINO-N-(PIPERIDIN-1-YL-PYRIDIN-3-YL) PYRAZOLO[1,5ALPHA]PYRIMIDINE-3-CARBOXAMID AS INHIBITOR OF ATR KINASE | VERTEX PHARMA (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-2941432-B1 | 2-AMINO-6-FLUORO-N-(5-FLUORO-4-(4-(4-(OXETAN-3-YL)PIPERAZINE-1-CARBONYL)PIPERIDIN-1-YL)PYRIDIN-3-YL)PYRAZOLO[1,5ALPHA]PYRIMIDINE-3-CARBOXAMIDE AS INHIBITOR OF ATR KINASE | VERTEX PHARMA (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9718827-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-01 | — | — | US | disclosed |
| US-9650381-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160347754-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-01 | — | — | US | disclosed |
| US-9340546-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2941432-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| WO-2014089379-A9 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140249157-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-04 | — | — | US | disclosed |
| US-20140163000-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-12 | — | — | US | disclosed |
| WO-2014089379-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249157-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PKM 832/4885AAK1 108/4885HTT 1973/4885 |
| US-20140163000-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PKM 832/4885AAK1 108/4885HTT 1973/4885 |
| US-11117900-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, TBK1 | PKM 841/4885AAK1 105/4885HTT 1997/4885 |
| US-20160347754-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | PKM 841/4885AAK1 105/4885HTT 1997/4885 |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PKM 832/4885AAK1 108/4885HTT 1973/4885 |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | PKM 841/4885AAK1 105/4885HTT 1997/4885 |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, CHEK1 | PKM 832/4885AAK1 108/4885HTT 1973/4885 |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, TBK1 | PKM 841/4885AAK1 105/4885HTT 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.